CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.
CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.
0
CIRM-Funded Clinical Trials
| Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
|---|---|---|---|---|---|---|
| Leukemia, Acute Myeloid (AML) | Joseph Paul Woodard | Immune-Onc Therapeutics | Phase 1 | Recruiting | 106 | |
| Blood Cancer Solid Tumors |
Professor Irving L Weissman MD | Stanford University | Phase 1 | Completed | 88 | |
| B cell cancers Leukemia Leukemia, Acute Myeloid (AML) |
Dr. Matthew H Porteus | Stanford University | Phase 1 | Recruiting | 22 | |
| B cell cancers Leukemia |
Dr. David B. Miklos | Stanford University | Phase 1 | Active, not recruiting | 56 | |
| B cell cancers Leukemia |
Thomas J Kipps | University of California, San Diego | Phase 1/2 | Active, not recruiting | 102 | |
| Blood Cancer | Thomas J Kipps | University of California, San Diego | Phase 1 | Completed | 26 | |
| Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1 | Completed | 10 | |
| Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1/2 | Completed | 42 | |
| B cell cancers | Dr. Paul Finnegan | Angiocrine Bioscience, Inc. | Phase 3 | Closed | 130 | |
| Leukemia, Acute Myeloid (AML) | Rochelle Emery | Senti Biosciences, Inc. | Phase 1 | Launching | N/A | |
| Leukemia, Acute Myeloid (AML) | Dr. Colleen Delaney | Nohla Therapeutics Inc | Phase 2 | Closed | 146 | |
| Leukemia, Acute Myeloid (AML) | Mark Chao | Forty Seven Inc. | Phase 1 | Closed | 258 | |
| Leukemia, Acute Myeloid (AML) | Elizabeth Budde | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
| Multiple Myeloma | Rajesh Belani MD | Poseida Therapeutics, Inc. | Phase 1 | Closed | 105 | |
| HIV-related Lymphoma HIV/AIDS |
Dr Mehrdad Abedi | University of California, Davis | Phase 1/2 | Active, not recruiting | 11 |
